FDA Focus: What Axinn's Practice Chair Is Watching
Chad Landmon, head of the U.S. Food and Drug Administration practice at Axinn Veltrop & Harkrider LLP, tells Law360 he's been urging regulators to make drug exclusivity decisions more quickly, looking...To view the full article, register now.
Already a subscriber? Click here to view full article